CHICAGO, July 11, 2019
— On behalf of the millions of people living with Alzheimer’s disease and their families , the Alzheimer’s Association
is disappointed about the report today
from Amgen, Novartis and Banner Alzheimer’s Institute that a data review revealed no hope of benefit outweighing risk in the BACE1 inhibitor arm of the Generation Trials, and that — similar to recent results from some other BACE1 trials — there was a worsening in cognition in the treatment groups.
The Alzheimer’s field has never faced more challenges, but due to increased research funding it has never been more optimistic. We must push forward. We must advance all potential treatment targets and also explore methods for combining these approaches. We must diversify our treatment and prevention strategies, which has been a focus in the last few years and will lead to new generations of approaches to be pursued. No stone can be left unturned.
Even knowing the obstacles, we have never been as hopeful as we are today. The Alzheimer’s Association is confident that we will change the trajectory of this disease. Some of the advances that will generate those changes will be reported this coming week at the Alzheimer’s Association International Conference (AAIC)
in Los Angeles.
The Alzheimer’s Association is also encouraged to hear that the companies and Banner continue to be committed to finding more effective Alzheimer’s treatments and preventions, and that they will share the data as soon as possible so the research community can learn from these results. We acknowledge and are grateful to the researchers, participants and their families for their contributions. It is only through these commitments that we will find more effective treatments and preventions for this disease.
At the Alzheimer’s Association, we will not slow down in our fight against this terrible disease. Currently, more than 5 million Americans
are living with dementia due to Alzheimer’s disease. By 2050, this number could nearly triple to 14 million, so our efforts to change the course of Alzheimer’s disease must continue to be a priority.
The Alzheimer's Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit www.alz.org or call 800.272.3900..